02 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Novozymes has appointed Mr Peder Holk Nielsen as president and CEO, Novozymes. Mr Peder Holk Nielsen takes over as CEO from Mr Steen Riisgaard, who steps down after 12 years in the company's top post and 33 years in Novozymes and Novo Industri/Novo Nordisk.
"I am proud and honored to lead this great company forward," said Mr Peder Holk Nielsen. "Novozymes is in a very strong position, and we will continue with our overall strategy. Our success rests on our ability to bring new innovation to our customers, and our ability to find new ways biotechnology can help them improve their products and make more with less. A key focus for me will be to make sure we bring these innovations to the market even faster than we do today."
Mr Peder Holk Nielsen, 56, has played a central role in the development of Novozymes in its current form. His 28-year career in Novozymes and Novo Industri/Novo Nordisk spans management positions across business development, research and development, quality management and sales and marketing. Up until his appointment as CEO, he served as Executive Vice President and Head of Enzyme Business from 2007-2013.